Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

NCT02129062 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Slow accrual.

Conditions

Adult B Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]